-transparent.png){kind=logo}
The effects of a 12-week oral treatment with tiapamil (200 mg t.i.d.) were compared to those of placebo treatment in a group of 20 men with coronary heart disease. There was a slight reduction of anginal symptoms (p less than 0.05) and a tendency to less nitroglycerin consumption (p less than 0.07). There were no statistically significant differences between the treatments in blood pressure, exercise tolerance during repeated exercise tests, ECG conduction intervals, or routine laboratory tests. No adverse side-effects were encountered. It seems that tiapamil may be beneficial in preventing angina pectoris, but a higher oral dose must be used.
Related Publications
Y Salorinne, and
J J Himberg, and
E Eskelinen
January 1978,
Bollettino della Societa italiana di cardiologia,
Y Salorinne, and
J J Himberg, and
E Eskelinen
January 1977,
Duodecim; laaketieteellinen aikakauskirja,
Y Salorinne, and
J J Himberg, and
E Eskelinen
March 1958,
Circulation,
Y Salorinne, and
J J Himberg, and
E Eskelinen
August 1982,
ZFA. Zeitschrift fur Allgemeinmedizin,
Y Salorinne, and
J J Himberg, and
E Eskelinen
September 1992,
Giornale italiano di cardiologia,
Y Salorinne, and
J J Himberg, and
E Eskelinen
April 1986,
Medicina clinica,
Y Salorinne, and
J J Himberg, and
E Eskelinen
October 1990,
Journal of clinical pharmacology,
Y Salorinne, and
J J Himberg, and
E Eskelinen
July 1980,
The Medical journal of Australia,
Y Salorinne, and
J J Himberg, and
E Eskelinen
January 1982,
Clinical and experimental pharmacology & physiology. Supplement,
Y Salorinne, and
J J Himberg, and
E Eskelinen
October 1982,
Herz,
